Ibrutinib Approval Pending for Marginal Zone Lymphoma

Article

A supplemental New Drug Application has been submitted to the US Food and Drug Administration for marginal zone lymphoma (MZL), and if approved, ibrutinib (Imbruvica) will be the first therapy specifically approved for patients with MZL.

A new treatment option for patients with marginal zone lymphoma (MZL) may soon be available. A supplemental New Drug Application has been submitted to the US Food and Drug Administration for MZL, and if approved, ibrutinib (Imbruvica) will be the first therapy specifically approved for patients with MZL, a slow-growing form of non-Hodgkin lymphoma, and yet another indication for the medication. Currently, the drug is approved for mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and Waldenström’s macroglobulinemia (WM).

MZL, a B-cell malignancy, may soon be treated with ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor that shows promise in patients with MZL who have received at least one prior therapy. MZL is a B-cell lymphoma arising from lymphocytes at the margins, or edges of lymph nodes and various tissues, including the stomach, salivary glands, thyroid gland, eyes, lungs, and spleen; it accounts for approximately 12% of all cases of non-Hodgkin lymphoma in adults. Thus far, this lesser known lymphoma does not have an established course of treatment.

“We are encouraged by the results of this study of ibrutinib in yet another type of B-cell malignancy,” said Peter F. Lebowitz, MD, PhD, Global Oncology Head at Janssen, in a news release. “This FDA submission represents an exciting and important step towards a potential new treatment option for MZL patients who currently have a great unmet need. Currently there are no therapies approved for this rare form of cancer.”

The PCYC-1121 trial enrolled 63 patients with MZL from across the globe who had received at least one prior therapy, including splenic MZL (SMZL), nodal MZL (NMZL), and extranodal MZL (EMZL). Patients received ibrutinib 560 mg orally, once daily until progression or unacceptable toxicity. The primary endpoint of the study was overall response rate as assessed by an Independent Review Committee.

The use of this treatment is not without some risks. Adverse reactions (≥20%) in patients with B-cell malignancies (MCL, CLL/SLL), and WM) were neutropenia (64%), thrombocytopenia (63%), diarrhea (43%), anemia  (41%), musculoskeletal pain (30%), rash (29%), nausea (29%), bruising (29%), fatigue (27%), hemorrhage (21%), and pyrexia (21%).

This study is ongoing, but not recruiting participants.

Recent Videos
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Related Content
Clinical Implications Remain After Dasatinib CRL in CML/ALL

Clinical Implications Remain After Dasatinib CRL in CML/ALL

Ariana Pelosci
October 28th 2025
Article

The FDA's CRL for the HyNap formulation of dasatinib due to manufacturing issues does not affect the efficacy or availability of standard dasatinib.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

PET-adapted strategies enhance treatment for advanced classical Hodgkin lymphoma, optimizing outcomes through individualized escalation and de-escalation based on PET results.

Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era

Wael Abdulla Moh Khair, MD
October 26th 2025
Article

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

The FDA has set a Prescription Drug User Fee Act date of June 18, 2026, for approving this formulation of nilotinib in chronic myeloid leukemia.

FDA Accepts NDA for New Nilotinib Formulation in CML

Russ Conroy
October 23rd 2025
Article

The FDA has set a Prescription Drug User Fee Act date of June 18, 2026, for approving this formulation of nilotinib in chronic myeloid leukemia.

Furthermore, the physical and psychosocial health sub-component scores of the PedsQL showed 12.4-point and 12.0-point improvements from baseline at month 24.

Exa-Cel Improved HRQOL in Transfusion-Dependent β-Thalassemia

Tim Cortese
October 23rd 2025
Article

Exa-cel displayed MCID-exceeding, sustained mean changes from baseline across various HRQOL-related scores in transfusion-dependent β-thalassemia.